A Study to Measure Anti-Mullerian Hormone for the Prediction of Response to Ovarian Stimulation

Overview

About this study

The purpose of this study is to identify the measurement of anti-mullerian hormone present that can specifically identify a 90% prediction of a poor ovarian response to controlled ovarian stimulation in women presenting to general invitro fertilization clinics for evaluation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

All racial and ethnic backgrounds
Written informed consent obtained
≥ 21 and < 46 years of age at the time of the blood draw
Undergoing first cycle of ovarian stimulation for IVF or IVF/ICSI
Regular menstrual cycle between 21 and 35 days, inclusive
Both ovaries present
On day 2 to 4 of a spontaneous menstrual cycle within 3 months prior to starting ovarian stimulation
- Blood samples taken by venipuncture for assay of AMH, FSH and estradiol
- Transvaginal ultrasound scan performed to assess the total number of antral follicles (measuring 2 to 10 mm in average diameter)

Exclusion Criteria

Evidence of polycystic ovary syndrome using the Rotterdam criteria
- Any 2 of the following 3, after exclusion of related disorders
  - Oligo- or anovulation
  - Clinical and/or biochemical signs of hyperandrogenism
  - Polycystic ovaries
Surgically confirmed ovarian endometrioma
Any ovarian surgery within one year prior to enrollment and study blood draw
Ovarian cysts or follicles measuring ≥ 20 mm
Exposure to cytotoxic drugs or pelvic radiation therapy
Hormonal contraceptive use within two months prior to enrollment and study blood draw
Currently pregnant

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Charles Coddington, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Charles Coddington, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials